Evaluation of thyroid hormone levels and somatomedin-C (IGF-1) in patients with chronic obstructive pulmonary disease (COPD) and relation with the severity of the disease

Tuberkuloz ve Toraks

Volumn 57, Issue 4, 2009, Pages 369-375

  Coşkun, Funda ^a   Ege, Ercüment ^a   Uzaslan, Esra ^a   Ediger, Dane ^a   Karadaǧ, Mehmet ^a   Gözü, Oktay ^a  

^a ULUDAG UNIVERSITY   (Turkey)

Author keywords

COPD; IGF; Thyroid hormones

Indexed keywords

LIOTHYRONINE; SOMATOMEDIN C; THYROID HORMONE; THYROTROPIN; THYROXINE;

ADULT; ARTERIAL GAS; ARTICLE; BLOOD SAMPLING; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; LIOTHYRONINE BLOOD LEVEL; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; SAMPLE SIZE; THYROXINE BLOOD LEVEL;

BIOLOGICAL MARKERS; BLOOD GAS ANALYSIS; CASE-CONTROL STUDIES; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY FUNCTION TESTS; SEVERITY OF ILLNESS INDEX; THYROID HORMONES; THYROTROPIN; TRIIODOTHYRONINE;

EID: 73449124093     PISSN: 04941373     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Cherniack NS. Control of breathing in COPD. In: Cherniack NS (ed). Chronic Obstructive Pulmonary Disease. Philadelphia: WB Saunders Company, 1991: 117-26.
2. Creutzberg EC, Casaburi R. Endocrinological disturbances in chronic obstructive pulmonary disease. Eur Respir J 2003; 22(Suppl 46): 76-80.
3. Meek PM, Schwartzstein RM, Adams L, et al. Dyspnea, mechanisms, assessment, and management: A consensus statement. American Thoracic Society. Am J Respir Crit Care Med 1995; 159: 321-40.
4. Schols AMWJ, Buurman WA, Staal van den Brekel AJ, et al. Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease. Thorax 1996; 51: 819-24.
5. Pape GS, Friedman M, Underwood LE, Clemmons DR. The effects of growth hormone on weight gain and pulmonary function in patients with chronic obstructive pulmonary disease. Chest 1991; 99: 1495-500.
6. Burdet L, Muralt B, Schultz Y, et al. Administration of growth hormone to underweight patients with chronic obstructive pulmonary disease. A prospective, randomized, controlled study. Am J Respir Crit Care Med 1997; 156: 1800-6.
7. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J 2005; 26: 319-38.
8. Scalvini S, Volterrani M, Vitacca M, et al. Plasma hormone levels and haemodynamics in patients with chronic obstructive lung disease. Monaldi Arch Chest Dis 1996; 51: 380-6.
9. Debigare R, Marquis K, Cote CH, et al. Catabolic/anabolic balance and muscle wasting in patients with COPD. Chest 2003; 124: 83-9.
10. Spruit MA, Gosselink R, Troosters T, et al. Muscle force during an acute exacerbation in hospitalised patients with COPD and its relationship with CXCL8 and IGF-1. Thorax 2003; 58: 752-6.
11. Suchner U, Rothkopf MM, Stanislaus G, et al. Growth hormone and pulmonary disease. Metabolic effects in patients receiving parenteral nutrition. Arch Intern Med 1990; 150: 1225-30.
12. Iioka Y, Tatsumi K, Sugito K, et al. Effects of insulin-like growth factor on nitrogen balance during hypoxic exposure. Eur Respir J 2002; 20: 293-9.
13. Lewis MI, Horvitz GD, Clemmons DR, Fournier M. Role of IGF-1 and IGF-binding proteins within diaphragm muscle in modulating the effects of nandrolone. Am J Physiol Endocrinol Metab 2002; 282: 483-90.
14. Urban RJ, Bodenburg YH, Gilkison C, et al. Testosterone administration to elderly men increases skeletal muscle strength and protein synthesis. Am J Physiol 1995; 269: 820-6.
15. Brill KT, Weltman AL, Gentili A, et al. Single and combined effects of growth hormone and testosterone administration on measures of body composition, physical performance, mood, sexual function, bone turnover, and muscle gene expression in healthy older men. J Clin Endocrinol Metab 2002; 87: 5649-57.
16. Hugli O, Frascarolo P, Schutz Y, et al. Diet-induced thermogenesis in chronic obstructive pulmonary disease. Am Rev Respir Dis 1993; 148: 1479-83.
17. Dimopoulou I, Ilias I, Mastorakos G, et al. Effects of severity of chronic obstructive pulmonary disease on thyroid function. Metabolism 2001; 50: 1397-401.
18. Bratel T, Wennlund A, Carlstrom K. Impact of hypoxaemia on neuroendocrine function and catecholamine secretion in chronic obstructive pulmonary disease (COPD). Effects of long-term oxygen treatment. Respir Med 2000; 94: 1221-8.
19. Okutan O, Kartaloglu Z, Onde ME, et al. Pulmonary function tests and thyroid hormone concentrations in patients with chronic obstructive pulmonary disease. Med Princ Pract 2004; 13: 126-8.